

Psoriasis does not worsen total hip arthroplasty outcomes

February 18 2016



(HealthDay)—For patients undergoing total hip arthroplasty (THA),



neither psoriatic arthritis (PsA) nor cutaneous psoriasis (PsC) are risk factors for poor outcomes, according to a study published in the February issue of *Arthritis & Rheumatology*.

Lisa A. Mandl, M.D., M.P.H., from the Hospital for Special Surgery in New York City, and colleagues compared THA outcomes for patients with PsA or PsC with those of patients with osteoarthritis (OA). Data were included for 63 and 153 patients with validated PsA and PsC, respectively.

The researchers found that PsA and PsC patients had higher body mass index and more comorbidities than OA controls. Fifty-four and 8 percent of PsA and PsC patients were treated with biologics or nonbiologic disease-modifying antirheumatic drugs. The groups did not differ in pre- or postoperative Western Ontario and McMaster Universities OA Index scores for pain or function. OA controls had better summary scores on the Short-Form 36 mental component pre- and postoperatively (P = 0.006 and P risk factors for worse THA outcomes. All three groups had high satisfaction with outcome (P = 0.54).

"This is important information to convey to <u>patients</u> with either PsA or PsC who are contemplating surgical intervention with THA," the authors write.

One author disclosed ties to UpToDate. Two authors disclosed financial ties to Zimmer Biomet.

More information: Abstract

Full Text (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.



Citation: Psoriasis does not worsen total hip arthroplasty outcomes (2016, February 18) retrieved 3 July 2024 from

https://medicalxpress.com/news/2016-02-psoriasis-worsen-total-hip-arthroplasty.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.